Low Pathogenic Avian Influenza H9N2 strain has been a persistent challenge in poultry flocks and is known to cause year-round comorbidity, leading to significant economic losses.

Hester Biosciences Limited, one of the India’s leading animal health company, manufacturing vaccines and health products has received the manufacturing license from the Food & Drugs Control Administration to manufacture and market the Low Pathogenic Avian Influenza Vaccine, Inactivated H9N2 strain for poultry.

Low Pathogenic Avian Influenza H9N2 strain has been a persistent challenge in poultry flocks and is known to cause year-round comorbidity, leading to significant economic losses. H9N2 can lead to an irreversible drop in egg production in layers and performance loss in broilers. It can also lead to high mortality in the presence of other infections.

This license is a key regulatory milestone in advancing Hester’s prevention-led poultry healthcare portfolio. This vaccine has been developed from technology acquired from ICAR-NIHSAD via Agrinnovate India.

Hester Biosciences Limited is one of the India’s leading animal health company, manufacturing vaccines and health products since 1997. Hester has two divisions include Poultry Healthcare division and Animal Healthcare division (which includes Ruminants and Pet health segments).

It is the world’s largest manufacturer and supplier of PPR vaccine, having approximately 75 per cent of the world market. It has over 70 per cent market share in Goat Pox vaccine in India which is being used to immunise cattle against Lumpy Skin disease. It is the second largest poultry vaccine manufacturer, with approximately 35per cent market share in India. Hester’s vaccine capabilities include multiple platforms such as Chick Embryo Origin, Continuous Cell line, Tissue Culture and Fermentation based live as well as inactivated vaccines. Hester recognises the vision of ONE HEALTH and works on improving the health of animals by enabling better health for human beings.